Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an equity investment into DELFI Diagnostics, a U.S.-based developer of blood-based cancer tests, without disclosing the financial terms. The investment will enable DELFI to further develop its fragmentomics and artificial intelligence technologies, enhancing early cancer detection and treatment monitoring.
DELFI’s proprietary technology employs AI to analyze cell-free DNA (cfDNA) from patients and compare it with cfDNA profiles from the general population. The company has commercialized a lung cancer test that has demonstrated 80% sensitivity, proving effective even in the early stages of lung cancer.- Flcube.com
